SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Meltzer M, Franklin EC. Cryoglobulinemia—a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 1966; 40: 82836.
  • 2
    Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 19: 6214.
  • 3
    Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis 1990; 162: 56970.
  • 4
    Dispenzieri A, Gorevic PD. Cryoglobulinaemia. Hematol Oncol Clin North Am 1999; 13: 131549.
  • 5
    De Vita S, De Re V, Gasparotto D, Ballare M, Pivetta B, Ferraccioli G, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94102.
  • 6
    De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus–associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000; 96: 357884.
  • 7
    Carson D, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991; 87: 37983.
  • 8
    De Vita S, Quartuccio L, Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune process, or both? Autoimmun Rev 2008; 8: 959.
  • 9
    De Re V, Sansonno D, Simula MP, Caggiari L, Gasparotto D, Fabris M, et al. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 2006; 20: 114554.
  • 10
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis. Arthritis Rheum 2005; 52: 9115.
  • 11
    Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 6328.
  • 12
    Quartuccio L, De Marchi G, Fabris M, De Vita S. Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 2006; 4: 3678.
  • 13
    Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, et al. Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008; 58: 60411.
  • 14
    Tavoni A, Mosca M, Ferri C, Moriconi L, La Civita L, Lombardini F, et al. Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 Suppl 13: S1915.
  • 15
    Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia [letter]. Haematologica 1999; 84: 11578.
  • 16
    Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 382734.
  • 17
    Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101: 381826.
  • 18
    Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 305461.
  • 19
    Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45: 8426.
  • 20
    Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005; 80: 15604.
  • 21
    Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007; 125: 303.
  • 22
    Terrier B, Saadoun D, Sene D, Sellam J, Perard L, Coppere B, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus–related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60: 253140.
  • 23
    Ferri C, Sebastiani M, Cacoub C, Roccatello D, Scaini P, Tavoni A, et al. Effects of rituximab in a large series of patients with HCV-associated mixed cryoglobulinemia syndrome. Ann Rheum Dis 2010; 69 Suppl III: iii234-5.
  • 24
    Invernizzi F, Pietrogrande M, Sagmoso B. Classification of the cryoglobulinemic syndrome. Clin Exp Rheumatol 1995; 13 Suppl 13: S1238.
  • 25
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 26
    Pietrogrande M, De Vita S, Zignego A, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 44454.
  • 27
    Lamprecht P, Moosig F, Gause A, Herlyn K, Gross WL. Birmingham Vasculitis Activity Score, Disease Extent Index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis. Clin Exp Rheumatol 2000; 18: 31925.
  • 28
    De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, et al. Preliminary classification criteria for the cryoglobulinemic syndrome. Ann Rheum Dis 2011; 70: 118390.
  • 29
    Terrier B, Launay D, Kaplanski G, Hot A, Larroche C, Cathebras P, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) 2010; 62: 178795.
  • 30
    Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010; 363: 2856.
  • 31
    Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 61823.
  • 32
    Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 35574.
  • 33
    Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 97686.
  • 34
    Quartuccio L, Petrarca A, Mansutti E, Pieroni S, Calcabrini L, Avellini C, et al. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010; 28: 847.
  • 35
    Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111: 533441.
  • 36
    Quartuccio L, Salvin S, Fabris M, Sacco S, De Vita S. Disappearance of bone marrow B cell clonal expansion in patients with type II hepatitis C virus-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 2008; 67: 14945.
  • 37
    Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18: 76776.
  • 38
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med 2010; 363: 22132.
  • 39
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 21120.
  • 40
    Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford) 2005; 44: 406.
  • 41
    Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al. Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 34353.
  • 42
    Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMκ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus–induced vasculitis. Arthritis Rheum 2009; 60: 384855.
  • 43
    Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia. Blood 2010; 116: 32634.
  • 44
    Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 33542.
  • 45
    De Vita S. Treatment of mixed cryoglobulinemia: a rheumatology perspective. Clin Exp Rheumatol 2011; 29: S99103.